protein

Recombinant Human LINGO-1 Protein, CF

9737-LG-050

50 ug

618 USD

9737-LG-050

Recombinant Human LINGO-1 Protein, CF

50 ug

The Recombinant Human LINGO-1 Protein, CF from R&D Systems is derived from HEK293. The Recombinant Human LINGO-1 Protein, CF has been validated for the following applications: Bioactivity.

LINGO-1

Proteins and Enzymes

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose.

Unconjugated

>80%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Human

82-112 kDa, reducing conditions

60 kDa

Measured by its binding ability in a functional ELISA. When Biotinylated Recombinant Human Nogo Receptor Fc Chimera is present at 2.5 ╡g/mL, the concentration of Recombinant Human LINGO-1 that produces 50% of the optimal binding response is 0.4-2.4 ╡g/mL.

<0.10 EU per 1 ╡g of the protein by the LAL method.

Recombinant Human LINGO-1 Protein Binding Activity

Q96FE5-1

Bioactivity

Human embryonic kidney cell, HEK293-derived human LINGO-1 protein Thr40-Thr556, with a C-terminal 6-His tag

HEK293

618 USD

FLJ14594, LERN1, LERN1UNQ201, leucine rich repeat and Ig domain containing 1, leucine rich repeat neuronal 6A, Leucine-rich repeat and immunoglobilin domain-containing protein 1, Leucine-rich repeat neuronal protein 1, Leucine-rich repeat neuronal protein 6A, LINGO1, LRRN6A, LRRN6Aleucine-rich repeat neuronal 6A, MGC17422

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, <= -20 ░C as supplied. 2 weeks, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, <= -20 ░C under sterile conditions after reconstitution.